ReviewCell proliferation2021
Liver microphysiological platforms for drug metabolism applications.
Review in Cell proliferation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Microphysiological systems as an emerging in vitro approach for the evaluation of drug absorption, distribution, metabolism, and excretion and toxicity.Drug metabolism and disposition: the biological fate of chemicals · 2025Review
- Emerging biotechnologies for engineering liver organoids.Bioactive materials · 2025Review
- Deciphering the cell type-specific and zonal distribution of drug-metabolizing enzymes, transporters, and transcription factors in livers of mice using single-cell transcriptomics.Drug metabolism and disposition: the biological fate of chemicals · 2025Article
- Astragalus Injection Modulates the Pharmacokinetics of Doxorubicin and CYP450 Enzymes.Current pharmaceutical design · 2025Article
- The Current State of Biotransformation Science - Industry Survey of In Vitro and In Vivo Practices, Clinical Translation, and Future Trends.Pharmaceutical research · 2024Article
- Tailoring epilepsy treatment: personalized micro-physiological systems illuminate individual drug responses.Annals of medicine and surgery (2012) · 2024Review
- An Insight on Microfluidic Organ-on-a-Chip Models for PMACS omega · 2024Review
- ABCG2 polymorphisms and susceptibility to ARV-associated hepatotoxicity.Molecular genetics & genomic medicine · 2024Article
- Gut-liver microphysiological systems revealed potential crosstalk mechanism modulating drug metabolism.PNAS nexus · 2024Article
- INTEDE 2.0: the metabolic roadmap of drugs.Nucleic acids research · 2024Article
- Comparative Pharmacokinetic Study of Rhubarb Anthraquinones in Normal and Nonalcoholic Fatty Liver Disease Rats.European journal of drug metabolism and pharmacokinetics · 2024Article
- Assessing immune hepatotoxicity of troglitazone with a versatile liver-immune-microphysiological-system.Frontiers in pharmacology · 2024Article
- Placing steroid hormones within the human ABCC3 transporter reveals a compatible amphiphilic substrate-binding pocket.The EMBO journal · 2023Article
- Recent Advances in Organ-on-Chips Integrated with Bioprinting Technologies for Drug Screening.Advanced healthcare materials · 2023Review
- Design, Simulation, and Evaluation of Polymer-Based Microfluidic Devices via Computational Fluid Dynamics and Cell Culture "On-Chip".Biosensors · 2023Article
- Article
- In vitro construction of liver organoids with biomimetic lobule structure by a multicellular 3D bioprinting strategy.Cell proliferation · 2023Article
- Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery.Pharmaceutics · 2023Review
- Microphysiological Drug-Testing Platform for Identifying Responses to Prodrug Treatment in Primary Leukemia.Advanced healthcare materials · 2023Article
- Development of a method of passaging and freezing human iPS cell-derived hepatocytes to improve their functions.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Drug development is a costly and lengthy process with low success rates. To improve the efficiency of drug development, there has been an increasing need in developing alternative methods able to eliminate toxic compounds early in the drug development pipeline. Drug metabolism plays a key role in determining the efficacy of a drug and its potential side effects. Since drug metabolism occurs mainly in the liver, liver cell-based alternative engineering platforms have been growing in the last decade. Microphysiological liver cell-based systems called liver-on-a-chip platforms can better recapitulate the environment for human liver cells in laboratory settings and have the potential to reduce the number of animal models used in drug development by predicting the response of the liver to a drug in vitro. In this review, we discuss the liver microphysiological platforms from the perspective of drug metabolism studies. We highlight the stand-alone liver-on-a-chip platforms and multi-organ systems integrating liver-on-a-chip devices used for drug metabolism mimicry in vitro and review the state-of-the-art platforms reported in the last few years. With the development of more robust and reproducible liver cell-based microphysiological platforms, the drug development field has the potential of reducing the costs and lengths associated with currently existing drug testing methods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.